ArticleDermatology practical & conceptual2025
Assessing Psychosocial Burden in Psoriasis Patients Using the PRISM-RII Tool: A Comprehensive Evaluation.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome.Psoriasis (Auckland, N.Z.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriasis is a chronic, immune-mediated inflammatory disease that significantly impacts patients' quality of life due to its visible lesions and associated stigma. Psychological comorbidities are prevalent among psoriasis patients.
objectivesThis study aimed to evaluate the utility of the Pictorial Representation of Illness and Self Measure Revised II (PRISM-RII) tool in assessing the psychosocial burden, including internalized stigma, in psoriasis patients.
methodsA cross-sectional study was conducted with 190 psoriasis patients recruited from a university hospital dermatology treatment center. Participants completed the PRISM-RII Psoriasis Internalized Stigma Scale (PISS), Hospital Anxiety and Depression Scale (HADS), and Dermatology Life Quality Index (DLQI). Clinical severity was measured using the Psoriasis Area and Severity Index (PASI).
resultsSignificant correlations were observed between PRISM-RII parameters and measures of quality of life, internalized stigma, anxiety, and depression. Our study revealed significant differences in PASI scores among different Illness Perception Measures (IPM). A negative correlation was found between PASI and Self-Illness Separation (SIS), suggesting that increased disease severity is associated with a higher perceived burden of illness. Additionally, significant negative correlations were observed between SIS and DLQI, HADS, and PISS. Patients with larger IPM reported higher levels of anxiety, depression, and internalized stigma, as well as lower treatment satisfaction.
conclusionsThe PRISM-RII tool effectively captures the psychosocial burden of psoriasis including internalized stigmatization, highlighting the need to address both physical and psychological aspects in clinical practice. Incorporating PRISM-RII into routine assessments can enhance patient-centered care by identifying and addressing the psychosocial dimensions of psoriasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.